Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

Trimi Health vs Next Vial

Two GLP-1 deals, scored on the same six factors. Trimi Health lands a Value Score of 89, Next Vial a 62. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

Trimi Health

#3 · Grade A · Great Deal

Est. first month

$99/mo

Save ~93% vs brand-name
Get this deal Full Trimi Health review →
VS

Next Vial

#350 · Grade C · Watch List

Est. first month

From $250/mo (compounded)

Save ~81% vs brand-name
Get this deal Full Next Vial review →

The verdict

Better value: Trimi Health

Trimi Health takes it on Value Score, 89 to 62 an est. $99/mo first month, with no teaser step-up baked in. Next Vial isn't out of it: People seeking compounded GLP-1 care with LegitScript certification and a named pharmacy partner.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealTrimi HealthNext Vial
Value Score89 (A)62 (C)
Est. first month$99/moFrom $250/mo (compounded)
Save vs brand-name~93%~81%
Semaglutide$99/moFrom $250/mo (compounded)
Tirzepatide$125/moNot disclosed
Both moleculesYesNo
PricingFlat — no step-upWatch
CoverageAll 50 states49 states

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

95
Lowest Real Price
62
Trimi Health: 95. Next Vial: 62.
84
No Teaser-Rate Bait
38
Trimi Health: 84. Next Vial: 38.
98
Nationwide Availability
88
Trimi Health: 98. Next Vial: 88.
94
Both Molecules
70
Trimi Health: 94. Next Vial: 70.
82
Easy Cancellation
58
Trimi Health: 82. Next Vial: 58.
70
Reputation
80
Trimi Health: 70. Next Vial: 80.

Trimi Health

The ultra-budget pick: two-digit semaglutide and a $125 tirzepatide — one of the lowest flat tirz stickers on the whole board — shipped to all 50 states.

Why it's a deal

  • Ultra-budget on both molecules — $99 semaglutide and a class-low $125 tirzepatide, flat with no teaser step-up
  • Tirzepatide at $125/mo undercuts most of the flat-fee field on the priciest molecule
  • Nationwide 50-state reach, so the low price isn't gated to a handful of states

The fine print

  • Not LegitScript-certified — do your own pharmacy diligence before you buy on price alone
  • Compounded injectable only — no FDA-approved brand-name or oral/sublingual route
  • Newer brand with a thin public track record

Next Vial

Fully online GLP-1 telehealth marketplace connecting patients with licensed providers for compounded semaglutide and tirzepatide injections, including microdose options.

Why it's a deal

  • LegitScript verified with named pharmacy partner (Manifest Pharmacy, Greer, SC)
  • No membership fees — one all-in price covering consultation, medication, and shipping
  • Compounded semaglutide, tirzepatide, and microdose options available
  • Free rushed shipping; serves 49 states nationwide
  • Board-certified physician oversight with ongoing provider support

The fine print

  • Tirzepatide pricing not listed publicly (starting price covers GLP-1 generally)
  • Compounded medications are not FDA-approved
  • Labs and nutritional coaching not disclosed
  • Microdose pricing not published on product page
  • Alaska not listed among served states
Get the Trimi Health deal Get the Next Vial deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores Trimi Health is ranked on the Trimi Health alternatives board, and the same list for the other side is on alternatives to Next Vial.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.